What happened

Shares of Doximity (NYSE: DOCS) went vertical after earnings. The stock closed Thursday at $20.66, then spiked as much as +105% to $42.39 in Friday's pre-market before cooling — during the regular session it traded around $32.80, up roughly 59%, as reported by Investing.com and Benzinga. For a company most people outside medicine have never heard of, that's one of the biggest single-day moves on the US market today.

Why it moved

Here's the twist: the headline numbers were only okay. Revenue was $156.6M, up just 7% year-over-year, beating the street's ~$151.7M — but earnings of 29 cents actually missed the 30-cent estimate by a penny. A 7% grower that misses on EPS doesn't normally double.

What lit the fuse was the AI story. CEO Jeff Tangney said the company's new AI search product earns more than 10× per search what it costs to run — a rare claim when most AI features lose money — and that its clinical assistant, Doximity Ask, topped US models on a physician-safety benchmark, beating Anthropic's latest model in the company's own testing. Management raised full-year revenue guidance to $671–681M (from $664–676M) and said most of the contracted AI-search revenue lands in fiscal Q3. In short, investors re-rated the whole company on a product that booked almost nothing this quarter.

The business

Doximity is basically LinkedIn for doctors. The company says more than 80% of US physicians are verified members. It doesn't charge them — it makes money by selling that audience: roughly 80% of revenue is marketing and advertising bought by pharma companies and hospitals, with the rest from workflow tools (its Dialer telehealth calling, e-fax, scheduling) and a hiring marketplace. About 93% of revenue is subscription at a ~92% gross margin. Today's AI catalyst is a new layer bolted onto that ad engine — not a new company — which is why one product's promise could move the entire stock.

Is it expensive?

Before the pop, DOCS was almost cheap by its own history: ~$3.8B market cap and a trailing P/E near 21, versus a five-year median around 51. After the ~59% jump it's worth about $6B with a trailing P/E back up near 34. Compare that to Veeva Systems (VEEV), the far-larger healthcare-software name at ~$37B and a trailing P/E around 32. So even post-jump, DOCS isn't obviously pricier than its blue-chip peer — but Veeva's multiple sits on steadier growth, while DOCS grew revenue just 7% last quarter. You're paying ~34× for a bet on the AI ramp, not for what the core ad business is doing right now.

Who it touches

• Digital-health peers — a profitable, self-funding AI product is a bullish read-through for names like Veeva (VEEV), Phreesia (PHR) and Teladoc (TDOC).
• Pharma advertisers — Doximity's paying customers; a stickier platform means more pricing power over their ad budgets.
• The "vertical AI" trade — proof a narrow, expert AI tool can earn many times its compute cost, which is the core bull case for specialist software.

What to watch

The one thing that flips this: the AI-search revenue is still mostly a promise. Q1 booked close to zero, and management points to fiscal Q3 for the bulk of it. If those conversions slip or land soft, a ~34× multiple on a 7% grower unwinds fast — and note the company also trimmed the midpoint of its adjusted-EBITDA guide by about $10M even as it lifted revenue. This is a story-and-multiple move, not a numbers blowout.

As of Fri Aug 7, ~12:45 PM ET. Sources: Investing.com, Benzinga, Schaeffer's, StockTwits. For discussion and education only — not investment advice. Verify before acting.